Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVLO NASDAQ:FBIO NASDAQ:FPRX NASDAQ:SCPH NASDAQ:TLC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.02$9K0.7912,688 shs900 shsFBIOFortress Biotech$1.99+3.1%$1.83$1.33▼$2.89$58.84M1.75279,531 shs228,309 shsFPRXFive Prime Therapeutics$38.00$37.94$2.61▼$38.90$1.77B4.41.98 million shsN/ASCPHscPharmaceuticals$4.08+3.0%$3.50$1.94▼$5.65$215.39M0.38386,226 shs264,990 shsTLCTaiwan Liposome$7.00$7.10$4.07▼$7.70$294.54M0.99133,095 shs12,421 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVLOEvelo Biosciences0.00%0.00%0.00%0.00%+150.00%FBIOFortress Biotech+1.05%+6.04%-3.50%+33.10%+10.29%FPRXFive Prime Therapeutics0.00%0.00%0.00%0.00%0.00%SCPHscPharmaceuticals+2.59%+1.02%-5.71%+80.82%-9.38%TLCTaiwan Liposome0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AFBIOFortress Biotech2.1419 of 5 stars3.51.00.00.00.63.30.6FPRXFive Prime TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASCPHscPharmaceuticals4.1364 of 5 stars3.54.00.04.20.61.70.6TLCTaiwan LiposomeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVLOEvelo Biosciences 0.00N/AN/AN/AFBIOFortress Biotech 3.00Buy$21.00955.28% UpsideFPRXFive Prime Therapeutics 0.00N/AN/AN/ASCPHscPharmaceuticals 3.00Buy$14.00244.40% UpsideTLCTaiwan Liposome 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AFBIOFortress Biotech$57.78M1.02N/AN/A($0.06) per share-33.17FPRXFive Prime Therapeutics$14.87M119.01N/AN/A$4.13 per share9.20SCPHscPharmaceuticals$36.33M5.91N/AN/A$0.27 per share15.06TLCTaiwan Liposome$3.63M81.14N/AN/A$0.83 per share8.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/AN/AFBIOFortress Biotech-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)FPRXFive Prime Therapeutics-$137.20M-$3.92N/AN/AN/A-554.71%-75.84%-49.08%N/ASCPHscPharmaceuticals-$85.15M-$1.91N/AN/AN/A-216.24%-594.07%-73.54%8/13/2025 (Estimated)TLCTaiwan Liposome-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/ALatest FPRX, SCPH, FBIO, EVLO, and TLC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SCPHscPharmaceuticals-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVLOEvelo BiosciencesN/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/AFPRXFive Prime TherapeuticsN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVLOEvelo BiosciencesN/AN/AN/AFBIOFortress Biotech1.741.721.55FPRXFive Prime TherapeuticsN/A5.355.35SCPHscPharmaceuticals3.865.484.61TLCTaiwan Liposome0.673.013.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVLOEvelo Biosciences0.31%FBIOFortress Biotech96.51%FPRXFive Prime Therapeutics67.28%SCPHscPharmaceuticals89.52%TLCTaiwan Liposome0.22%Insider OwnershipCompanyInsider OwnershipEVLOEvelo Biosciences1.02%FBIOFortress Biotech27.90%FPRXFive Prime Therapeutics6.40%SCPHscPharmaceuticals4.78%TLCTaiwan LiposomeN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVLOEvelo Biosciences12018.98 million18.79 millionNo DataFBIOFortress Biotech17029.57 million21.32 millionOptionableFPRXFive Prime Therapeutics8746.57 millionN/AOptionableSCPHscPharmaceuticals3052.79 million50.27 millionOptionableTLCTaiwan Liposome2,02042.08 millionN/ANot OptionableFPRX, SCPH, FBIO, EVLO, and TLC HeadlinesRecent News About These CompaniesWhat is the TLC Diet?July 8 at 7:59 AM | news-medical.netNThis TLC star bares it all on stage while another rushes into a new relationshipJuly 8 at 7:59 AM | msn.com‘Virgins’ new episode on TLC tonight, how to watch for freeJuly 8 at 7:59 AM | masslive.comMFans Can't Believe TLC's Dr. Now 'Finally Smiled at Something' in 'Adorable' New VideoJuly 8 at 7:59 AM | msn.comAngelo Dawkins Feared Career-Ending Knee Injury In TLC Match – ‘I’m Afraid Of Heights!’July 6 at 12:08 AM | ewrestlingnews.comEThe True and Tragic Story of TLC’s Lisa ‘Left Eye’ LopesJuly 4, 2025 | yahoo.com‘90 Day Fiancé: Happily Ever After?’ Season 9 Cast Photos: Meet The 8 Couples Returning To TLC SeriesJuly 4, 2025 | msn.comTLC Recovery House celebrating 4th Anniversary and Recovery RallyJuly 4, 2025 | msn.comAdult virgins break taboos and take huge emotional risks in tonight’s must-see TLC episodeJuly 1, 2025 | msn.comTLC’s ‘Virgins’ airs new episode tonight - How to watch for freeJuly 1, 2025 | masslive.comM‘Match Me Abroad’ season 2, episode 2; how to watch TLC realityJune 29, 2025 | mlive.comMTLC ‘Virgins’ Star Rhasha Will Have You Blushing With Her Unique Definition of BDSM (Exclusive)June 27, 2025 | usmagazine.comUTLC brings colour, connection to Niche Market Art ShowcaseJune 26, 2025 | citizen.co.zaCPhiladelphia Leadership: Emily Gatto, Director, TLC WellnessJune 26, 2025 | msn.comManchester's TLC Foundation seeks $200,000 to avoid closing Diyeso-Lewis House for homeless childrenJune 26, 2025 | stamfordadvocate.comSHow to watch ‘Match Me Abroad’ Season 2 TLC dating show free or on demandJune 23, 2025 | msn.comTLC’s hit show ‘Match Me Abroad’ returns after 2-year break: How you can watch the new season freeJune 23, 2025 | msn.comStill A Virgin At 34, Reading Man Tries Tantra And Pickup Lines On New TLC ShowJune 12, 2025 | dailyvoice.comD‘1,000-Lb Roomies’ new episode: How to stream new series on TLC for freeJune 12, 2025 | masslive.comMTLC ‘Virgins’ docuseries premiere: How to watch for free todayJune 11, 2025 | cleveland.comCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFPRX, SCPH, FBIO, EVLO, and TLC Company DescriptionsEvelo Biosciences NASDAQ:EVLO$0.0005 0.00 (0.00%) As of 02:32 PM EasternEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Fortress Biotech NASDAQ:FBIO$1.99 +0.06 (+3.11%) Closing price 04:00 PM EasternExtended Trading$1.95 -0.04 (-2.01%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Five Prime Therapeutics NASDAQ:FPRXFive Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.scPharmaceuticals NASDAQ:SCPH$4.08 +0.12 (+3.03%) Closing price 04:00 PM EasternExtended Trading$4.07 -0.01 (-0.34%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Taiwan Liposome NASDAQ:TLCTaiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
